These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 20813005

  • 1. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
    Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC, Vose JM, Chigrinova E, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJ, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Lambotte O, Uccella S, Pinotti G, Pruneri G, Martinelli G, Young KH, Tibiletti MG, Rinaldi A, Zucca E, Kwee I, Bertoni F.
    Br J Haematol; 2010 Nov; 151(3):221-31. PubMed ID: 20813005
    [Abstract] [Full Text] [Related]

  • 2. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [Abstract] [Full Text] [Related]

  • 3. Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.
    Chae YS, Kim JG, Sohn SK, Moon JH, Kim SN, Lee SJ, Park TI, Lee MH.
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):571-7. PubMed ID: 19629486
    [Abstract] [Full Text] [Related]

  • 4. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

  • 5. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ.
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [Abstract] [Full Text] [Related]

  • 6. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP.
    J Clin Oncol; 2011 Feb 20; 29(6):690-7. PubMed ID: 21189393
    [Abstract] [Full Text] [Related]

  • 7. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Testoni M, Kwee I, Greiner TC, Montes-Moreno S, Vose J, Chan WC, Chiappella A, Baldini L, Ferreri AJ, Gaidano G, Mian M, Zucca E, Bertoni F.
    Br J Haematol; 2011 Oct 20; 155(2):274-7. PubMed ID: 21488860
    [No Abstract] [Full Text] [Related]

  • 8. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, Kim DH.
    Clin Cancer Res; 2009 Mar 15; 15(6):2107-15. PubMed ID: 19276283
    [Abstract] [Full Text] [Related]

  • 9. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC, Best JH.
    Cancer; 2005 Apr 15; 103(8):1644-51. PubMed ID: 15756658
    [Abstract] [Full Text] [Related]

  • 10. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast.
    Aviles A, Neri N, Nambo MJ.
    Am J Clin Oncol; 2012 Apr 15; 35(2):126-9. PubMed ID: 21325938
    [Abstract] [Full Text] [Related]

  • 11. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
    Kim IS, Kim DC, Kim HG, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Kim S, Lee GW.
    Cancer Genet Cytogenet; 2010 Jan 01; 196(1):31-7. PubMed ID: 19963133
    [Abstract] [Full Text] [Related]

  • 12. Improving outcomes for patients with diffuse large B-cell lymphoma.
    Flowers CR, Sinha R, Vose JM.
    CA Cancer J Clin; 2010 Jan 01; 60(6):393-408. PubMed ID: 21030533
    [Abstract] [Full Text] [Related]

  • 13. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.
    J Clin Oncol; 2006 Jul 01; 24(19):3121-7. PubMed ID: 16754935
    [Abstract] [Full Text] [Related]

  • 14. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM.
    J Clin Oncol; 2005 Aug 01; 23(22):5027-33. PubMed ID: 15955905
    [Abstract] [Full Text] [Related]

  • 15. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
    Yi SH, Xu Y, Zou DH, An G, Zhao YZ, Qi JY, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2009 May 01; 30(5):307-12. PubMed ID: 19799125
    [Abstract] [Full Text] [Related]

  • 16. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
    Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH, Kim SW, Park BH, Yoon SO, Huh J, Lee SW, Suh C.
    Eur J Haematol; 2010 Aug 01; 85(2):149-57. PubMed ID: 20477862
    [Abstract] [Full Text] [Related]

  • 17. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups.
    Br J Haematol; 2008 Feb 01; 140(4):411-9. PubMed ID: 18162120
    [Abstract] [Full Text] [Related]

  • 19. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B.
    J Clin Oncol; 2005 Jun 20; 23(18):4117-26. PubMed ID: 15867204
    [Abstract] [Full Text] [Related]

  • 20. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Castillo JJ, Sinclair N, Beltrán BE, Song MK, Ilic I, Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, Stachurski D, Butera JN.
    Leuk Res; 2013 Apr 20; 37(4):386-91. PubMed ID: 23352640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.